ClinVar Miner

Submissions for variant NM_001323289.2(CDKL5):c.638G>A (p.Gly213Glu) (rs1569215629)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000699805 SCV000828532 pathogenic Early infantile epileptic encephalopathy 2; Angelman syndrome-like 2018-02-23 criteria provided, single submitter clinical testing This sequence change replaces glycine with glutamic acid at codon 213 of the CDKL5 protein (p.Gly213Glu). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and glutamic acid. This variant is not present in population databases (ExAC no frequency). This variant has been reported to be de novo in an individual affected with infantile spasms (PMID: 23934111). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. A different missense substitution at this codon (p.Gly213Arg) has been reported in an individual affected with atypical Rett syndrome and early-onset epileptic encephalopathy (PMID: 27187038). For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.